Hoechst Marion Roussel Lorelco market withdrawal, UT's Slow Fluoride go before advisory cmte. Nov. 16-17.
Executive Summary
HMR LORELCO WITHDRAWAL TO BE CONSIDERED BY ADVISORY COMMITTEE NOV. 17 as part of a two-day meeting of FDA's Endocrinologic & Metabolic Drugs Advisory Committee Nov. 16-17. Interneuron's dexfenfluramine and University of Texas Southwestern Medical Center's Slow Fluoride for osteoporosis will be reviewed Nov. 16. The advisory committee meeting will begin both days at 8 a.m. with an open public hearing until 8:30.